Armata Pharmaceuticals, Inc. (ARMP)
USD 1.13
(-9.6%)
USD 1.13
(-9.6%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 109.96 Million USD | 14.74% |
| 2022 | 95.83 Million USD | 37.36% |
| 2021 | 69.76 Million USD | 76.56% |
| 2020 | 39.51 Million USD | 55.26% |
| 2019 | 25.45 Million USD | 114.11% |
| 2018 | 11.88 Million USD | 6.72% |
| 2017 | 11.13 Million USD | -38.79% |
| 2016 | 18.19 Million USD | -42.23% |
| 2015 | 31.49 Million USD | 10.05% |
| 2014 | 28.61 Million USD | -24.59% |
| 2013 | 37.94 Million USD | 71.93% |
| 2012 | 22.07 Million USD | 0.0% |
| 2008 | 7.15 Million USD | -74.89% |
| 2007 | 28.47 Million USD | 63.02% |
| 2006 | 17.46 Million USD | -64.21% |
| 2005 | 48.79 Million USD | -30.25% |
| 2004 | 69.96 Million USD | 21.32% |
| 2003 | 57.67 Million USD | 9.41% |
| 2002 | 52.71 Million USD | -25.8% |
| 2001 | 71.03 Million USD | -19.25% |
| 2000 | 87.97 Million USD | 542.15% |
| 1999 | 13.7 Million USD | -15.43% |
| 1998 | 16.2 Million USD | 65.31% |
| 1997 | 9.8 Million USD | -60.96% |
| 1996 | 25.1 Million USD | 25.5% |
| 1995 | 20 Million USD | 17.65% |
| 1994 | 17 Million USD | 40.5% |
| 1993 | 12.1 Million USD | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q2 | 108.31 Million USD | -10.01% |
| 2024 Q1 | 120.35 Million USD | 9.45% |
| 2023 Q4 | 109.96 Million USD | -2.48% |
| 2023 FY | 109.96 Million USD | 14.74% |
| 2023 Q2 | 101.21 Million USD | -6.96% |
| 2023 Q3 | 112.76 Million USD | 11.41% |
| 2023 Q1 | 108.77 Million USD | 13.51% |
| 2022 Q4 | 95.83 Million USD | 3.18% |
| 2022 Q2 | 100.98 Million USD | -6.29% |
| 2022 FY | 95.83 Million USD | 37.36% |
| 2022 Q1 | 107.76 Million USD | 54.46% |
| 2022 Q3 | 92.88 Million USD | -8.02% |
| 2021 Q3 | 42.67 Million USD | -11.62% |
| 2021 FY | 69.76 Million USD | 76.56% |
| 2021 Q2 | 48.28 Million USD | -8.64% |
| 2021 Q1 | 52.84 Million USD | 33.73% |
| 2021 Q4 | 69.76 Million USD | 63.5% |
| 2020 Q4 | 39.51 Million USD | -13.48% |
| 2020 Q2 | 49.46 Million USD | 12.15% |
| 2020 Q3 | 45.67 Million USD | -7.65% |
| 2020 Q1 | 44.1 Million USD | 73.28% |
| 2020 FY | 39.51 Million USD | 55.26% |
| 2019 Q4 | 25.45 Million USD | -13.15% |
| 2019 Q3 | 29.3 Million USD | -16.07% |
| 2019 Q2 | 34.91 Million USD | 263.07% |
| 2019 Q1 | 9.61 Million USD | -19.1% |
| 2019 FY | 25.45 Million USD | 114.11% |
| 2018 Q4 | 11.88 Million USD | 11.94% |
| 2018 Q1 | 14.39 Million USD | 29.28% |
| 2018 Q2 | 11.72 Million USD | -18.61% |
| 2018 FY | 11.88 Million USD | 6.72% |
| 2018 Q3 | 10.61 Million USD | -9.39% |
| 2017 Q3 | 13.78 Million USD | -8.77% |
| 2017 Q2 | 15.1 Million USD | 5.62% |
| 2017 FY | 11.13 Million USD | -38.79% |
| 2017 Q4 | 11.13 Million USD | -19.18% |
| 2017 Q1 | 14.3 Million USD | -21.4% |
| 2016 Q1 | 28.26 Million USD | -10.26% |
| 2016 Q2 | 29.27 Million USD | 3.6% |
| 2016 Q3 | 26.03 Million USD | -11.08% |
| 2016 Q4 | 18.19 Million USD | -30.12% |
| 2016 FY | 18.19 Million USD | -42.23% |
| 2015 Q3 | 34.07 Million USD | -6.31% |
| 2015 FY | 31.49 Million USD | 10.05% |
| 2015 Q4 | 31.49 Million USD | -7.59% |
| 2015 Q2 | 36.37 Million USD | -5.78% |
| 2015 Q1 | 38.6 Million USD | 34.9% |
| 2014 Q1 | 34.35 Million USD | -9.48% |
| 2014 Q2 | 31.26 Million USD | -8.99% |
| 2014 Q3 | 28.41 Million USD | -9.09% |
| 2014 FY | 28.61 Million USD | -24.59% |
| 2014 Q4 | 28.61 Million USD | 0.7% |
| 2013 Q4 | 37.94 Million USD | 0.0% |
| 2013 FY | 37.94 Million USD | 71.93% |
| 2012 FY | 22.07 Million USD | 0.0% |
| 2009 Q3 | 4.53 Million USD | 11.11% |
| 2009 Q2 | 4.07 Million USD | -25.48% |
| 2009 Q1 | 5.47 Million USD | -23.48% |
| 2008 FY | 7.15 Million USD | -74.89% |
| 2008 Q1 | 24.24 Million USD | -14.84% |
| 2008 Q2 | 22.71 Million USD | -6.33% |
| 2008 Q3 | 19.18 Million USD | -15.54% |
| 2008 Q4 | 7.15 Million USD | -62.73% |
| 2007 Q1 | 21.61 Million USD | 23.76% |
| 2007 FY | 28.47 Million USD | 63.02% |
| 2007 Q2 | 37.47 Million USD | 73.34% |
| 2007 Q4 | 28.47 Million USD | -9.63% |
| 2007 Q3 | 31.5 Million USD | -15.92% |
| 2006 FY | 17.46 Million USD | -64.21% |
| 2006 Q1 | 51.08 Million USD | 4.68% |
| 2006 Q2 | 22.98 Million USD | -55.0% |
| 2006 Q4 | 17.46 Million USD | -12.42% |
| 2006 Q3 | 19.94 Million USD | -13.23% |
| 2005 Q4 | 48.79 Million USD | -6.91% |
| 2005 FY | 48.79 Million USD | -30.25% |
| 2005 Q3 | 52.42 Million USD | -13.16% |
| 2005 Q1 | 65.41 Million USD | -6.51% |
| 2005 Q2 | 60.37 Million USD | -7.71% |
| 2004 Q1 | 77.11 Million USD | 33.71% |
| 2004 Q2 | 73.27 Million USD | -4.98% |
| 2004 Q3 | 67.38 Million USD | -8.04% |
| 2004 Q4 | 69.96 Million USD | 3.83% |
| 2004 FY | 69.96 Million USD | 21.32% |
| 2003 Q1 | 50.62 Million USD | -3.96% |
| 2003 Q4 | 57.67 Million USD | -8.48% |
| 2003 Q2 | 62.31 Million USD | 23.09% |
| 2003 Q3 | 63.01 Million USD | 1.12% |
| 2003 FY | 57.67 Million USD | 9.41% |
| 2002 Q1 | 62.09 Million USD | -12.59% |
| 2002 FY | 52.71 Million USD | -25.8% |
| 2002 Q2 | 62.59 Million USD | 0.8% |
| 2002 Q4 | 52.71 Million USD | -11.63% |
| 2002 Q3 | 59.65 Million USD | -4.7% |
| 2001 Q1 | 83.31 Million USD | -5.3% |
| 2001 Q4 | 71.03 Million USD | -3.12% |
| 2001 Q3 | 73.32 Million USD | -2.37% |
| 2001 Q2 | 75.1 Million USD | -9.86% |
| 2001 FY | 71.03 Million USD | -19.25% |
| 2000 Q2 | 35.34 Million USD | -9.1% |
| 2000 Q3 | 84.77 Million USD | 139.84% |
| 2000 Q4 | 87.97 Million USD | 3.77% |
| 2000 FY | 87.97 Million USD | 542.15% |
| 2000 Q1 | 38.88 Million USD | 183.86% |
| 1999 Q2 | 11 Million USD | -16.67% |
| 1999 FY | 13.7 Million USD | -15.43% |
| 1999 Q4 | 13.7 Million USD | -3.52% |
| 1999 Q1 | 13.2 Million USD | -18.52% |
| 1999 Q3 | 14.2 Million USD | 29.09% |
| 1998 Q1 | 6.7 Million USD | -31.63% |
| 1998 Q2 | 15.8 Million USD | 135.82% |
| 1998 Q3 | 12.2 Million USD | -22.78% |
| 1998 Q4 | 16.2 Million USD | 32.79% |
| 1998 FY | 16.2 Million USD | 65.31% |
| 1997 FY | 9.8 Million USD | -60.96% |
| 1997 Q1 | 21.2 Million USD | -15.54% |
| 1997 Q2 | 17.3 Million USD | -18.4% |
| 1997 Q3 | 14.2 Million USD | -17.92% |
| 1997 Q4 | 9.8 Million USD | -30.99% |
| 1996 Q1 | 17.4 Million USD | -13.0% |
| 1996 FY | 25.1 Million USD | 25.5% |
| 1996 Q4 | 25.1 Million USD | -9.71% |
| 1996 Q2 | 30.5 Million USD | 75.29% |
| 1996 Q3 | 27.8 Million USD | -8.85% |
| 1995 Q4 | 20 Million USD | -7.83% |
| 1995 FY | 20 Million USD | 17.65% |
| 1995 Q3 | 21.7 Million USD | 82.35% |
| 1995 Q1 | 14.4 Million USD | -15.29% |
| 1995 Q2 | 11.9 Million USD | -17.36% |
| 1994 FY | 17 Million USD | 40.5% |
| 1994 Q4 | 17 Million USD | -8.6% |
| 1994 Q2 | 21 Million USD | 0.0% |
| 1994 Q3 | 18.6 Million USD | -11.43% |
| 1993 FY | 12.1 Million USD | 0.0% |
| 1993 Q4 | 12.1 Million USD | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| AIM ImmunoTech Inc. | 19.38 Million USD | -467.38% |
| Ampio Pharmaceuticals, Inc. | 5.73 Million USD | -1817.085% |
| Actinium Pharmaceuticals, Inc. | 81.44 Million USD | -35.016% |
| Azitra, Inc. | 5.11 Million USD | -2049.63% |
| Can-Fite BioPharma Ltd. | 9.98 Million USD | -1000.851% |
| Chromocell Therapeutics Corporation | 96.39 Thousand USD | -113981.19% |
| Calidi Biotherapeutics, Inc. | 10.01 Million USD | -997.555% |
| CEL-SCI Corporation | 30.52 Million USD | -260.204% |
| iBio, Inc. | 28.73 Million USD | -282.696% |
| Lineage Cell Therapeutics, Inc. | 101.01 Million USD | -8.855% |
| MAIA Biotechnology, Inc. | 7.56 Million USD | -1353.233% |
| Matinas BioPharma Holdings, Inc. | 65.57 Million USD | -67.684% |
| Navidea Biopharmaceuticals, Inc. | 4.37 Million USD | -2415.414% |
| NovaBay Pharmaceuticals, Inc. | 9.03 Million USD | -1117.224% |
| NanoViricides, Inc. | 12.82 Million USD | -757.563% |
| Oragenics, Inc. | 4.96 Million USD | -2114.188% |
| BiomX Inc. | 58.15 Million USD | -89.085% |
| BiomX Inc. | 58.15 Million USD | -89.085% |
| Protalix BioTherapeutics, Inc. | 84.43 Million USD | -30.237% |
| Palatin Technologies, Inc. | 10.74 Million USD | -923.657% |
| Scorpius Holdings, Inc. | 51.03 Million USD | -115.457% |
| Theriva Biologics, Inc. | 60.21 Million USD | -82.631% |